Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment
- PMID: 35819037
Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment
Abstract
Renal cell carcinoma (RCC) is the most common type of urogenital cancer. It has a mortality rate of 30-40% and is more commonly seen in men than women. In addition to gender, other risk factors of RCC include obesity, hypertension, smoking, and chronic kidney disease. Following the improvements in diagnostic tests, such as CT and MRI imaging, the incidence of patients diagnosed with RCC has rapidly increased over the past decades. The most common type of RCC, based on histological and molecular subtypes, is clear cell carcinoma which occurs frequently due to mutations in the VHL gene. Nephron-sparing surgery is a selective technique to maintain kidneys in patients while radical nephrectomy and partial nephrectomy are used to remove small tumors. In addition to surgical approaches, adjuvant therapy and targeted therapy are applied in patients with metastatic RCC. In this review, we give an overview of the most recent research on RCC which would help physicians to better manage patients with RCC.
Keywords: genetics; kidney cancer; renal cell carcinoma.
Copyright by Società Italiana di Nefrologia SIN, Rome, Italy.
Similar articles
-
[Renal cell carcinoma: what is new in 2010?].Urologe A. 2011 Sep;50 Suppl 1:216-8. doi: 10.1007/s00120-011-2676-6. Urologe A. 2011. PMID: 21837489 Review. German.
-
Incidence of benign pathologic lesions at partial nephrectomy for presumed RCC renal masses: Japanese dual-center experience with 176 consecutive patients.Urology. 2008 Sep;72(3):598-602. doi: 10.1016/j.urology.2008.04.054. Epub 2008 Jul 23. Urology. 2008. PMID: 18649929
-
Renal cell carcinoma: current status and future prospects.Cancer Treat Rev. 2005 Nov;31(7):536-45. doi: 10.1016/j.ctrv.2005.07.009. Epub 2005 Oct 17. Cancer Treat Rev. 2005. PMID: 16236454 Review.
-
Incidental renal cell carcinoma and nephron sparing surgery.Curr Opin Urol. 2001 May;11(3):281-6. doi: 10.1097/00042307-200105000-00007. Curr Opin Urol. 2001. PMID: 11371781 Review.
-
Renal cell carcinoma: presentation, staging, and surgical treatment.Semin Oncol. 2000 Apr;27(2):160-76. Semin Oncol. 2000. PMID: 10768595 Review.
Cited by
-
Bioinformatics analysis and experimental validation of m6A and cuproptosis-related lncRNA NFE4 in clear cell renal cell carcinoma.Discov Oncol. 2024 May 26;15(1):187. doi: 10.1007/s12672-024-01023-y. Discov Oncol. 2024. PMID: 38797784 Free PMC article.
-
Characterization of FOLH1 Expression in Renal Cell Carcinoma.Cancers (Basel). 2024 May 13;16(10):1855. doi: 10.3390/cancers16101855. Cancers (Basel). 2024. PMID: 38791934 Free PMC article.
-
Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review.Medicine (Baltimore). 2024 May 24;103(21):e38268. doi: 10.1097/MD.0000000000038268. Medicine (Baltimore). 2024. PMID: 38788027 Free PMC article. Review.
-
Case report: Uterine leiomyoma with fumarate hydratase deficiency.Front Med (Lausanne). 2024 May 9;11:1391978. doi: 10.3389/fmed.2024.1391978. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38784227 Free PMC article.
-
Poria acid inhibit the growth and metastasis of renal cell carcinoma by inhibiting the PI3K/akt/NF-κb signaling pathway.Heliyon. 2024 May 11;10(10):e31106. doi: 10.1016/j.heliyon.2024.e31106. eCollection 2024 May 30. Heliyon. 2024. PMID: 38779018 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous